EcoDrugPlus

Bruton Tyrosine Kinase

Ensembl ID : ENSSTUG00000012054
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSSTUG00000034957
Gene Symbol: LOC115156578
3 Cross references
180 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSSTUG00000015275
Gene Symbol: LOC115170172
3 Cross references
182 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSSTUG00000020319
Gene Symbol: LOC115154971
2 Cross references
185 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSSTUG00000026324
Gene Symbol: CCR9
3 Cross references
187 Possible Orthologues:

C-X-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSSTUG00000008161
Gene Symbol: LOC115155947
2 Cross references
268 Possible Orthologues:

C-X-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSSTUG00000013662
Gene Symbol: LOC115161336
2 Cross references
269 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSSTUG00000037502
Gene Symbol: CXCR4
3 Cross references
195 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSSTUG00000013977
Gene Symbol: CXCR4
3 Cross references
195 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSSTUG00000026930
Gene Symbol: LOC115161317
2 Cross references
350 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSSTUG00000005395
Gene Symbol: LOC115153971
3 Cross references
192 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSSTUG00000012628
Gene Symbol: LOC115148506
3 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).